1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

Shirish M Gadgeel ,J.A Alatorre Alexander,M Maclennan,Michael S Mathisen ,Vijay Bhagawati-Prasad ,Daniel S.w Tan ,Zoe June Assaf ,Filippo De Marinis ,Martin J Slade ,Virote Sriuranpong ,Maurice Pérol ,Solange Peters ,Tania Ochi Lohmann ,J Y Han ,Natasha B Leighl ,Ernest Nadal ,Tony S K Mok ,Gilberto De Castro ,Sarah M Paul ,Rafał Dziadziuszko

doi:10.1016/j.annonc.2023.09.2394

1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

Shirish M Gadgeel , J.A Alatorre Alexander + Show 18 more

https://doi.org/10.1016/j.annonc.2023.09.2394

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

#Advanced ALK #Biomarker Subgroups + Show 5 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.